Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1800–1805. doi: 10.1038/sj.bjc.6990287

Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma

L Assersohn 1, A Norman 1, D Cunningham 1, T Benepal 1, P J Ross 1, J Oates 1
PMCID: PMC2362782  PMID: 10206296

Abstract

Every year, 31 230 men and women are diagnosed with colorectal carcinoma, and up to 60% of these will ultimately develop advanced disease. However, there is little information to identify which patients are most likely to benefit from palliative chemotherapy. This analysis is unique in evaluating how the site of metastasis influences response and survival. A database of 497 patients treated within randomized clinical trials using 5-Fluorouracil (5FU)-based chemotherapy at the Royal Marsden Hospital was analysed. The potential for site of metastasis as a predictive variable for response to chemotherapy and survival was examined, in addition to other clinical parameters. The presence of liver metastases was a better predictor for overall response than either performance status or number of metastatic sites on presentation. Probability of response was significantly decreased by a raised serum carcinoembryonic antigen (CEA) and presence of peritoneal metastases. In liver metastases, a normal serum albumin was as significant a predictor for response as good performance status. The most important predictor for survival was initial performance status. The number of metastatic sites on presentation had no influence on survival. Site of metastasis can predict for response to 5FU-based chemotherapy and patients should be stratified according to the involved site of metastasis in the future. © 1999 Cancer Research Campaign

Keywords: colorectal cancer, metastatic site, prognostic, chemotherapy

Full Text

The Full Text of this article is available as a PDF (79.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allen-Mersh T. G., Earlam S., Fordy C., Abrams K., Houghton J. Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet. 1994 Nov 5;344(8932):1255–1260. doi: 10.1016/s0140-6736(94)90750-1. [DOI] [PubMed] [Google Scholar]
  2. Buroker T. R., O'Connell M. J., Wieand H. S., Krook J. E., Gerstner J. B., Mailliard J. A., Schaefer P. L., Levitt R., Kardinal C. G., Gesme D. H., Jr Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol. 1994 Jan;12(1):14–20. doi: 10.1200/JCO.1994.12.1.14. [DOI] [PubMed] [Google Scholar]
  3. Chang A. E., Steinberg S. M., Culnane M., White D. E. Determinants of survival in patients with unresectable colorectal liver metastases. J Surg Oncol. 1989 Apr;40(4):245–251. doi: 10.1002/jso.2930400409. [DOI] [PubMed] [Google Scholar]
  4. Conti J. A., Kemeny N. E., Saltz L. B., André A. M., Grossano D. D., Bertino J. R. Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. Cancer. 1995 Feb 1;75(3):769–774. doi: 10.1002/1097-0142(19950201)75:3<769::aid-cncr2820750304>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  5. Finan P. J., Marshall R. J., Cooper E. H., Giles G. R. Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg. 1985 May;72(5):373–377. doi: 10.1002/bjs.1800720514. [DOI] [PubMed] [Google Scholar]
  6. Fountzilas G., Gossios K., Zisiadis A., Svarna E., Skarlos D., Pavlidis N. Prognostic variable in patients with advanced colorectal cancer treated with fluorouracil and leucovorin-based chemotherapy. Med Pediatr Oncol. 1996 May;26(5):305–317. doi: 10.1002/(SICI)1096-911X(199605)26:5<305::AID-MPO2>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
  7. Gorlick R., Metzger R., Danenberg K. D., Salonga D., Miles J. S., Longo G. S., Fu J., Banerjee D., Klimstra D., Jhanwar S. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J Clin Oncol. 1998 Apr;16(4):1465–1469. doi: 10.1200/JCO.1998.16.4.1465. [DOI] [PubMed] [Google Scholar]
  8. Hill M., Norman A., Cunningham D., Findlay M., Nicolson V., Hill A., Iveson A., Evans C., Joffe J., Nicolson M. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol. 1995 Jun;13(6):1297–1302. doi: 10.1200/JCO.1995.13.6.1297. [DOI] [PubMed] [Google Scholar]
  9. Hill M., Norman A., Cunningham D., Findlay M., Watson M., Nicolson V., Webb A., Middleton G., Ahmed F., Hickish T. Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer. J Clin Oncol. 1995 Sep;13(9):2317–2323. doi: 10.1200/JCO.1995.13.9.2317. [DOI] [PubMed] [Google Scholar]
  10. Johnston P. G., Lenz H. J., Leichman C. G., Danenberg K. D., Allegra C. J., Danenberg P. V., Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995 Apr 1;55(7):1407–1412. [PubMed] [Google Scholar]
  11. Kosmidis P. A., Tsavaris N., Skarlos D., Theocharis D., Samantas E., Pavlidis N., Briassoulis E., Fountzilas G. Fluorouracil and leucovorin with or without interferon alfa-2b in advanced colorectal cancer: analysis of a prospective randomized phase III trial. Hellenic Cooperative Oncology Group. J Clin Oncol. 1996 Oct;14(10):2682–2687. doi: 10.1200/JCO.1996.14.10.2682. [DOI] [PubMed] [Google Scholar]
  12. Kouri M., Nordling S., Kuusela P., Pyrhönen S. Poor prognosis associated with elevated serum CA 19-9 level in advanced colorectal carcinoma, independent of DNA ploidy or SPF. Eur J Cancer. 1993;29A(12):1691–1696. doi: 10.1016/0959-8049(93)90106-p. [DOI] [PubMed] [Google Scholar]
  13. Kouri M., Pyrhönen S., Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol. 1992 Feb;49(2):78–85. doi: 10.1002/jso.2930490204. [DOI] [PubMed] [Google Scholar]
  14. Leichman C. G., Lenz H. J., Leichman L., Danenberg K., Baranda J., Groshen S., Boswell W., Metzger R., Tan M., Danenberg P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol. 1997 Oct;15(10):3223–3229. doi: 10.1200/JCO.1997.15.10.3223. [DOI] [PubMed] [Google Scholar]
  15. Mayer R. J. Chemotherapy for metastatic colorectal cancer. Cancer. 1992 Sep 1;70(5 Suppl):1414–1424. doi: 10.1002/1097-0142(19920901)70:3+<1414::aid-cncr2820701533>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  16. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  17. Poon M. A., O'Connell M. J., Moertel C. G., Wieand H. S., Cullinan S. A., Everson L. K., Krook J. E., Mailliard J. A., Laurie J. A., Tschetter L. K. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989 Oct;7(10):1407–1418. doi: 10.1200/JCO.1989.7.10.1407. [DOI] [PubMed] [Google Scholar]
  18. Recchia F., Nuzzo A., Lalli A., Lombardo M., Di Lullo L., Fabiani F., Fanini R., Venturoni L., Torchio P., Peretti G. Randomized trial of 5-fluorouracil and high-dose folinic acid with or without alpha-2B interferon in advanced colorectal cancer. Am J Clin Oncol. 1996 Jun;19(3):301–304. doi: 10.1097/00000421-199606000-00019. [DOI] [PubMed] [Google Scholar]
  19. Ross P., Norman A., Cunningham D., Webb A., Iveson T., Padhani A., Prendiville J., Watson M., Massey A., Popescu R. A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol. 1997 Oct;8(10):995–1001. doi: 10.1023/a:1008263516099. [DOI] [PubMed] [Google Scholar]
  20. Scheithauer W., Rosen H., Kornek G. V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993 Mar 20;306(6880):752–755. doi: 10.1136/bmj.306.6880.752. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Seymour M. T., Slevin M. L., Kerr D. J., Cunningham D., James R. D., Ledermann J. A., Perren T. J., McAdam W. A., Harper P. G., Neoptolemos J. P. Randomized trial assessing the addition of interferon alpha-2a to fluorouracil and leucovorin in advanced colorectal cancer. Colorectal Cancer Working Party of the United Kingdom Medical Research Council. J Clin Oncol. 1996 Aug;14(8):2280–2288. doi: 10.1200/JCO.1996.14.8.2280. [DOI] [PubMed] [Google Scholar]
  22. Stangl R., Altendorf-Hofmann A., Charnley R. M., Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet. 1994 Jun 4;343(8910):1405–1410. doi: 10.1016/s0140-6736(94)92529-1. [DOI] [PubMed] [Google Scholar]
  23. Steinberg J., Erlichman C., Gadalla T., Fine S., Wong A. Prognostic factors in patients with metastatic colorectal cancer receiving 5-fluorouracil and folinic acid. Eur J Cancer. 1992;28A(11):1817–1820. doi: 10.1016/0959-8049(92)90011-p. [DOI] [PubMed] [Google Scholar]
  24. Webb A., Scott-Mackie P., Cunningham D., Norman A., Andreyev J., O'Brien M., Bensted J. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol. 1995 Jul;6(6):581–587. doi: 10.1093/oxfordjournals.annonc.a059248. [DOI] [PubMed] [Google Scholar]
  25. Yeh K. H., Shun C. T., Chen C. L., Lin J. T., Lee W. J., Lee P. H., Chen Y. C., Cheng A. L. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer. 1998 May 1;82(9):1626–1631. doi: 10.1002/(sici)1097-0142(19980501)82:9<1626::aid-cncr5>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES